Sold as Inocor. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 15, 2026, FDA lists 4 applications for Inamrinone Lactate (sold as Inocor), first approved Jul 31, 1984, with 1 new use approved and 0 published complete response letters.
| Jul 31, 1984 | InocorNDA 18700 ยท New molecular entity | Sanofi Aventis US | 19 | Discontinued |
| Aug 3, 1998 | Amrinone LactateANDA 74616 | Hospira | 2 | Discontinued |
| May 9, 2000 | Amrinone LactateANDA 75513 | Hikma | 1 | Marketed |
| May 10, 2000 | Amrinone LactateANDA 75542 | Baxter Hlthcare Corp | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sanofi Aventis US
Hikma
Baxter Hlthcare Corp